Artelo Biosciences

Historical price data

Artelo Biosciences is a clinical-stage biotech focused on developing therapeutics that modulate lipid-signaling pathways, with a primary mission to improve treatments for cancer and related conditions. Its most advanced asset, ART27.13, has demonstrated promising Phase 2 efficacy in reversing weight loss and improving lean body mass in cancer anorexia-cachexia syndrome (CACS), positioning it as a potential first-in-class therapy. The company's strategy involves advancing this lead program while leveraging its platform to develop additional assets targeting the endocannabinoid system and fatty acid binding proteins. Artelo operates as a public, micro-cap company, navigating the high-risk, high-reward landscape of early-stage drug development.

A small molecule platform focused on modulating lipid-signaling pathways, with core expertise in targeting the endocannabinoid system (CB1/CB2 receptors) and intracellular fatty acid binding proteins (FABPs) to develop therapeutics for cancer and related conditions.

In CACS, ART27.13 competes in a vacant market with no approved drugs, holding a lead over other investigational approaches like anamorelin and SARMs due to its positive Phase 2 data and peripheral restriction. In the broader FABP5 inhibitor space for oncology, the competitive field is more crowded and earlier-stage, requiring superior data to differentiate.